Top

Published in:

01-08-2019 | Myocardial Infarction | Original Article

Randomized comparison between 2-link cell design biolimus A9-eluting stent and 3-link cell design everolimus-eluting stent in patients with de novo true coronary bifurcation lesions: the BEGIN trial

Authors: Masahiro Yamawaki, Toshiya Muramatsu, Kazuhiro Ashida, Koichi Kishi, Yoshihiro Morino, Yoshihisa Kinoshita, Takashi Fujii, Yuichi Noguchi, Shingo Hosogi, Kazuya Kawai, Kiyoshi Hibi, Yoshisato Shibata, Hiroshi Ohira, Yasuhiro Morita, Yasuhiro Tarutani, Mikihito Toda, Yoshihisa Shimada, Yuji Ikari, Jiro Ando, Yutaka Hikichi, Yoritaka Otsuka, Yasushi Fuku, Shigenori Ito, Harumi Katoh, Kazushige Kadota, Yoshiaki Ito, Kazuaki Mitsudo

Published in: Heart and Vessels | Issue 8/2019

Abstract

The appropriate stent platform for treating coronary bifurcation lesions (CBLs) remains controversial. Previous bench tests have demonstrated the superiority of a 2-link cell design to 3-link cell design for creating inter-strut dilation at the side branch ostium. This randomized multicenter prospective BEGIN trial compared the biodegradable polymer-based biolimus A9-eluting stent (2-link BES) with the durable polymer-based cobalt chromium everolimus-eluting stent (3-link EES) in 226 patients with de novo CBLs. Patients with true bifurcations, defined as > 50% stenosis in the main vessel and side branch (SB) and an SB diameter > 2.25 mm, were enrolled. Guide wire re-crossing to the distal cell (near the carina) in the jailed SB and final kissing inflation were recommended. The SB angiographic endpoint was < 50% stenosis diameter. Left-main CBLs (13.5% vs. 13.0%) and 2-stent technique (30.6% vs. 22.6%) rates were similar. The primary endpoints (minimum lumen diameter at the SB ostium measured at an independent core laboratory at the 8-month follow-up) were comparable (1.64 ± 0.50 mm vs. 1.63 ± 0.51 mm, p = 0.976). There was no significant difference in composite outcomes of cardiac death, myocardial infarction, or target vascular revascularization at 12 months (7.4% vs. 8.0%, p = 0.894). Two-link BES and 3-link EES showed similar 8-month angiographic and 1-year clinical outcomes for true CBLs.

Available only for authorised users

Louvard Y, Thomas M, Dzavik V, Hildick-Smith D, Galassi AR, Pan M, Burzotta F, Zelizko M, Dudek D, Ludman P, Sheiban I, Lassen JF, Darremont O, Kastrati A, Ludwig J, Iakovou I, Brunel P, Lansky A, Meerkin D, Legrand V, Medina A, Lefevre T (2008) Classification of coronary artery bifurcation lesions and treatments: time for a consensus! Catheter Cardiovasc Interv 71:175–183CrossRefPubMed

Natsuaki M, Morimoto T, Furukawa Y, Nakagawa Y, Kadota K, Yamaji K, Ando K, Shizuta S, Shiomi H, Tada T, Tazaki J, Kato Y, Hayano M, Abe M, Tamura T, Shirotani M, Matsuda M, Takahashi M, Ishii K, Tanaka M, Aoyama T, Doi O, Hattori R, Kato M, Suwa S, Takizawa A, Takatsu Y, Shinoda E, Eizawa H, Takeda T, Lee JD, Inoko M, Ogawa H, Hamasaki S, Horie M, Nohara R, Kambara H, Fujiwara H, Mitsudo K, Nobuyoshi M, Kita T, Kimura T (2014) Late adverse events after implantation of sirolimus-eluting stent and bare-metal stent: long-term (5–7 years) follow-up of the coronary revascularization demonstrating outcome study-Kyoto registry cohort-2. Circ Cardiovasc Interv 7:168–179CrossRefPubMed

Costa RA, Mintz GS, Carlier SG, Lansky AJ, Moussa I, Fujii K, Takebayashi H, Yasuda T, Costa JR Jr, Tsuchiya Y, Jensen LO, Cristea E, Mehran R, Dangas GD, Iyer S, Collins M, Kreps EM, Colombo A, Stone GW, Leon MB, Moses JW (2005) Bifurcation coronary lesions treated with the “crush” technique: an intravascular ultrasound analysis. J Am Coll Cardiol 46:599–605CrossRefPubMed

Burzotta F, Trani C, Todaro D, Mariani L, Talarico GP, Tommasino A, Giammarinaro M, Niccoli G, Porto I, Leone AM, Mongiardo R, Mazzari MA, Schiavoni G, Crea F (2011) Prospective randomized comparison of sirolimus- or everolimus-eluting stent to treat bifurcated lesions by provisional approach. JACC Cardiovasc Interv 4:327–335CrossRefPubMed

Lee JM, Hahn JY, Kang J, Park KW, Chun WJ, Rha SW, Yu CW, Jeong JO, Jeong MH, Yoon JH, Jang Y, Tahk SJ, Gwon HC, Koo BK, Kim HS (2015) Differential prognostic effect between first- and second-generation drug-eluting stents in coronary bifurcation lesions: patient-level analysis of the Korean bifurcation pooled cohorts. JACC Cardiovasc Interv 8:1318–1331CrossRefPubMed

Murasato Y, Iwasaki K, Yamamoto T, Yagi T, Hikichi Y, Suematsu Y, Yamamoto T (2014) Optimal kissing balloon inflation after single-stent deployment in a coronary bifurcation model. EuroIntervention 10:934–941CrossRefPubMed

Hikichi Y, Umezu M, Node K, Iwasaki K (2017) Reduction in incomplete stent apposition area caused by jailed struts after single stenting at left main bifurcation lesions: micro-CT analysis using a three-dimensional elastic bifurcated coronary artery model. Cardiovasc Interv Ther 32:12–17CrossRefPubMed

Nakao F, Okamura T, Suetomi T, Yamada J, Nakamura T, Ueda T, Oda T, Kanemoto M, Ikeda Y, Fujii T, Yano M (2016) Differences of side branch jailing between left main-left anterior descending artery stenting and left main-left circumflex artery stenting with Nobori biolimus-eluting stent. Heart Vessels 31:1895–1903CrossRefPubMed

Pan M, Burzotta F, Trani C, Medina A, Suarez de Lezo J, Niccoli G, Romero M, Porto I, Mazuelos F, Leone AM, Martin P, Coluccia V, Suarez de Lezo J, Ojeda S, Crea F (2014) Three-year follow-up of patients with bifurcation lesions treated with sirolimus- or everolimus-eluting stents: SEAside and CORpal cooperative study. Rev Esp Cardiol (Engl Ed) 67:797–803CrossRef

10.

Pan M, Medina A, Suarez de Lezo J, Romero M, Segura J, Martin P, Suarez de Lezo J, Hernandez E, Mazuelos F, Ojeda S (2012) Randomized study comparing everolimus- and sirolimus-eluting stents in patients with bifurcation lesions treated by provisional side-branch stenting. Catheter Cardiovasc Interv 80:1165–1170CrossRefPubMed

11.

Costopoulos C, Latib A, Naganuma T, Sticchi A, Ferrarello S, Regazzoli D, Chieffo A, Figini F, Carlino M, Montorfano M, Naim C, Kawaguchi M, Gerasimou A, Giannini F, Godino C, Colombo A (2014) Comparison of abluminal biodegradable polymer biolimus-eluting stents and durable polymer everolimus-eluting stents in the treatment of coronary bifurcations. Catheter Cardiovasc Interv 83:889–895CrossRefPubMed

12.

Lam MK, Sen H, van Houwelingen KG, Lowik MM, van der Heijden LC, Kok MM, de Man FH, Linssen GC, Tandjung K, Doggen CJ, von Birgelen C (2015) Three-year clinical outcome of patients with bifurcation treatment with second-generation Resolute and Xience V stents in the randomized TWENTE trial. Am Heart J 169:69–77CrossRefPubMed

13.

Orvin K, Carrie D, Richardt G, Desmet W, Assali A, Werner G, Ikari Y, Fujii K, Goicolea J, Dangoisse V, Manari A, Saito S, Wijns W, Kornowski R (2016) Comparison of sirolimus eluting stent with bioresorbable polymer to everolimus eluting stent with permanent polymer in bifurcation lesions: results from CENTURY II trial. Catheter Cardiovasc Interv 87:1092–1100CrossRefPubMed

14.

Guerin P, Pilet P, Finet G, Goueffic Y, N’Guyen JM, Crochet D, Tijou I, Pacaud P, Loirand G (2010) Drug-eluting stents in bifurcations: bench study of strut deformation and coating lesions. Circ Cardiovasc Interv 3:120–126CrossRefPubMed

15.

Natsuaki M, Kozuma K, Morimoto T, Kadota K, Muramatsu T, Nakagawa Y, Akasaka T, Igarashi K, Tanabe K, Morino Y, Ishikawa T, Nishikawa H, Awata M, Abe M, Okada H, Takatsu Y, Ogata N, Kimura K, Urasawa K, Tarutani Y, Shiode N, Kimura T (2013) Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent: a randomized, controlled, noninferiority trial. J Am Coll Cardiol 62:181–190CrossRefPubMed

16.

Natsuaki M, Kozuma K, Morimoto T, Kadota K, Muramatsu T, Nakagawa Y, Akasaka T, Igarashi K, Tanabe K, Morino Y, Ishikawa T, Nishikawa H, Awata M, Abe M, Okada H, Takatsu Y, Ogata N, Kimura K, Urasawa K, Tarutani Y, Shiode N, Kimura T (2015) Final 3-year outcome of a randomized trial comparing second-generation drug-eluting stents using either biodegradable polymer or durable polymer: NOBORI biolimus-eluting versus XIENCE/PROMUS everolimus-eluting stent trial. Circ Cardiovasc Interv 8

17.

Niemela M, Kervinen K, Erglis A, Holm NR, Maeng M, Christiansen EH, Kumsars I, Jegere S, Dombrovskis A, Gunnes P, Stavnes S, Steigen TK, Trovik T, Eskola M, Vikman S, Romppanen H, Makikallio T, Hansen KN, Thayssen P, Aberge L, Jensen LO, Hervold A, Airaksinen J, Pietila M, Frobert O, Kellerth T, Ravkilde J, Aaroe J, Jensen JS, Helqvist S, Sjogren I, James S, Miettinen H, Lassen JF, Thuesen L (2011) Randomized comparison of final kissing balloon dilatation versus no final kissing balloon dilatation in patients with coronary bifurcation lesions treated with main vessel stenting: the Nordic-Baltic Bifurcation Study III. Circulation 123:79–86CrossRefPubMed

18.

Yu CW, Yang JH, Song YB, Hahn JY, Choi SH, Choi JH, Lee HJ, Oh JH, Koo BK, Rha SW, Jeong JO, Jeong MH, Yoon JH, Jang Y, Tahk SJ, Kim HS, Gwon HC (2015) Long-term clinical outcomes of final kissing ballooning in coronary bifurcation lesions treated with the 1-stent technique: results from the COBIS II registry (Korean coronary bifurcation stenting registry). JACC Cardiovasc Interv 8:1297–1307CrossRefPubMed

19.

Steigen TK, Maeng M, Wiseth R, Erglis A, Kumsars I, Narbute I, Gunnes P, Mannsverk J, Meyerdierks O, Rotevatn S, Niemela M, Kervinen K, Jensen JS, Galloe A, Nikus K, Vikman S, Ravkilde J, James S, Aaroe J, Ylitalo A, Helqvist S, Sjogren I, Thayssen P, Virtanen K, Puhakka M, Airaksinen J, Lassen JF, Thuesen L (2006) Randomized study on simple versus complex stenting of coronary artery bifurcation lesions: the Nordic bifurcation study. Circulation 114:1955–1961CrossRefPubMed

20.

Yamawaki M, Murasato Y, Kinoshita Y, Fujii K, Fujino Y, Shinke T, Takeda Y, Yamada S, Shimada Y, Tsukahara R, Muramatsu T, Suzuki T (2016) Mechanism of residual lumen stenosis at the side branch ostium after final kissing balloon inflation: a volumetric intracoronary ultrasound study of coronary bifurcation lesions. J Interv Cardiol 29:188–196CrossRefPubMed

21.

Okamura T, Nagoshi R, Fujimura T, Murasato Y, Yamawaki M, Ono S, Serikawa T, Hikichi Y, Norita H, Nakao F, Sakamoto T, Shinke T, Shite J (2018) Impact of guidewire recrossing point into stent jailed side branch for optimal kissing balloon dilatation: core lab 3D optical coherence tomography analysis. EuroIntervention 13:e1785–e1793CrossRefPubMed

22.

Nagoshi R, Okamura T, Murasato Y, Fujimura T, Yamawaki M, Ono S, Serikawa T, Hikichi Y, Nakao F, Sakamoto T, Shinke T, Kijima Y, Kozuki A, Shibata H, Shite J (2018) Feasibility and usefulness of three-dimensional optical coherence tomography guidance for optimal side branch treatment in coronary bifurcation stenting. Int J Cardiol 250:270–274CrossRefPubMed

23.

Ruiz-Salmeron RJ, Valenzuela LF, Perez I, Fuentes M, Rodriguez-Leiras S, Vizcaino M, Carrascosa C, Marcos F (2013) Approach to coronary bifurcation lesions using the everolimus-eluting stent: comparison between a simple strategy and a complex strategy with T-stenting. Rev Esp Cardiol (Engl Ed) 66:636–643CrossRef

24.

Koo BK, Kang HJ, Youn TJ, Chae IH, Choi DJ, Kim HS, Sohn DW, Oh BH, Lee MM, Park YB, Choi YS, Tahk SJ (2005) Physiologic assessment of jailed side branch lesions using fractional flow reserve. J Am Coll Cardiol 46:633–637CrossRefPubMed

Title: Randomized comparison between 2-link cell design biolimus A9-eluting stent and 3-link cell design everolimus-eluting stent in patients with de novo true coronary bifurcation lesions: the BEGIN trial
Authors: Masahiro Yamawaki
Toshiya Muramatsu
Kazuhiro Ashida
Koichi Kishi
Yoshihiro Morino
Yoshihisa Kinoshita
Takashi Fujii
Yuichi Noguchi
Shingo Hosogi
Kazuya Kawai
Kiyoshi Hibi
Yoshisato Shibata
Hiroshi Ohira
Yasuhiro Morita
Yasuhiro Tarutani
Mikihito Toda
Yoshihisa Shimada
Yuji Ikari
Jiro Ando
Yutaka Hikichi
Yoritaka Otsuka
Yasushi Fuku
Shigenori Ito
Harumi Katoh
Kazushige Kadota
Yoshiaki Ito
Kazuaki Mitsudo
Publication date: 01-08-2019
Publisher: Springer Japan
Keywords: Myocardial Infarction
Everolimus
Published in: Heart and Vessels / Issue 8/2019
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI: https://doi.org/10.1007/s00380-019-01368-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Randomized comparison between 2-link cell design biolimus A9-eluting stent and 3-link cell design everolimus-eluting stent in patients with de novo true coronary bifurcation lesions: the BEGIN trial

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2019

Liraglutide suppresses atrial electrophysiological changes

Clinical characteristics and prognostic factors in acute coronary syndrome patients complicated with cardiogenic shock in Japan: analysis from the Japanese Circulation Society Cardiovascular Shock Registry

Linc00299/miR-490-3p/AURKA axis regulates cell growth and migration in atherosclerosis

Assessment of strut coverage of everolimus-eluting platinum chromium stent 2 weeks after implantation by optical coherence tomography

Edoxaban suppresses the progression of atrial fibrosis and atrial fibrillation in a canine congestive heart failure model

Correction to: Cell salvage processing of residual cardiopulmonary bypass volume in minimally invasive cardiac surgery